. "9 Haemophilus influenzae Type b Vaccines ." Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Casuality. Washington, DC: The National Academies Press, 1994.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality
TABLE 9-1 Characteristics of Hib Vaccines
Vaccine, (producer, trade name)
Polysaccharide
Protein Carrier
Age of Administration (date of licensure)
PRP
(Praxis, b Capsa 1; Lederle, HibImmune; Connaught, HibVAX)
g Centers for Disease Control and Prevention (1993).
dom demonstrated efficacy of the vaccine when given at ages 2, 3, and 4 months (Booy et al., 1992). Following the widespread distribution and administration of Hib conjugate vaccines, few cases of vaccine failure (a case of Hib disease occurring more than 14 days after the second or third doses) have been reported (Black et al., 1992a; Holmes et al., 1991; Santosham et al., 1992), and postlicensure studies have shown a marked decrease in the incidence of Hib disease in the United States (Adams et al., 1993; Black et al., 1992b; Broadhurst et al., 1993; Centers for Disease Control, 1990c; Murphy et al., 1993b).
The American Academy of Pediatrics and the Advisory Committee on Immunization Practices recommend that conjugate Hib vaccines be administered as two to three doses beginning at age 2 months and then a booster at 12 to 15 months.
